Literature DB >> 21833803

Effectiveness of repeat angiographic assessment in patients designated for radioembolization using yttrium-90 microspheres with initial extrahepatic accumulation of technitium-99m macroaggregated albumin: a single center's experience.

Oliver Dudeck1, Skadi Wilhelmsen, Gerhard Ulrich, David Löwenthal, Maciej Pech, Holger Amthauer, Jens Ricke.   

Abstract

PURPOSE: To evaluate the efficacy of a workflow consisting of repeat assessment in patients planned for yttrium-90 ((90)Y) radioembolization in case of nontarget visceral technetium-99m ((99m)Tc)-macroaggregated albumin (MAA) accumulation despite initial prophylactic coil embolization of nonhepatic arteries.
MATERIALS AND METHODS: In 341 patients with primary and secondary liver cancer, pretreatment hepatic angiograms, as well as single-photon emission computed tomography coregistered with magnetic resonance imaging scans, were obtained. Extrahepatic tracer deposition was identified in 33 patients (9.7%) necessitating repeat assessment. Images were reviewed to correlate the site of MAA accumulation with causative gastrointestinal vessels, and repeat angiograms served as reference standard.
RESULTS: At repeat angiography, the source of extrahepatic flow was identified and eliminated in 31 of 33 patients (93.9%). In 20 patients (60.6%), successful embolization of nontarget vessels was achieved, in 13 patients (39.4%), MAA was administered more distally. Afterward, extrahepatic MAA deposition was eliminated in 30 patients (90.9%).
CONCLUSION: The algorithm of repeat assessment in case of extrahepatic MAA accumulation has proven highly effective to eliminate extrahepatic shunting, thus decreasing the risk of postradioembolization complications due to inadvertent visceral microsphere deposition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833803     DOI: 10.1007/s00270-011-0252-5

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

Review 1.  The role of SPECT/CT in radioembolization of liver tumours.

Authors:  Hojjat Ahmadzadehfar; Heying Duan; Alexander R Haug; Stephan Walrand; Martha Hoffmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-18       Impact factor: 9.236

2.  Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization.

Authors:  Laurence Lenoir; Julien Edeline; Yann Rolland; Marc Pracht; Jean-Luc Raoul; Valérie Ardisson; Patrick Bourguet; Bruno Clément; Eveline Boucher; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

3.  Use of C-Arm Cone Beam CT During Hepatic Radioembolization: Protocol Optimization for Extrahepatic Shunting and Parenchymal Enhancement.

Authors:  Andor F van den Hoven; Jip F Prince; Bart de Keizer; Evert-Jan P A Vonken; Rutger C G Bruijnen; Helena M Verkooijen; Marnix G E H Lam; Maurice A A J van den Bosch
Journal:  Cardiovasc Intervent Radiol       Date:  2015-06-12       Impact factor: 2.740

4.  Gallbladder Radiation Protection in SIRT-Quantitative Anatomical Study of Hepatic Vasculature.

Authors:  Piotr Piasecki; Krzysztof Brzozowski; Piotr Ziecina; Marek Wierzbicki; Anna Budzynska; Andrzej Mazurek; Miroslaw Dziuk; Maciej Maciak; Edward Iller; Jerzy Narloch
Journal:  J Clin Med       Date:  2019-09-24       Impact factor: 4.241

5.  Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts?

Authors:  Jens M Theysohn; Marcus Ruhlmann; Stefan Müller; Alexander Dechene; Jan Best; Johannes Haubold; Lale Umutlu; Guido Gerken; Andreas Bockisch; Thomas C Lauenstein
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

6.  Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases.

Authors:  Maarten L J Smits; Andor F van den Hoven; Charlotte E N M Rosenbaum; Bernard A Zonnenberg; Marnix G E H Lam; Johannes F W Nijsen; Miriam Koopman; Maurice A A J van den Bosch
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.